DOI:

Detection of a necrotic core-rich, highly deformable plaque in an angiographically non-diseased proximal LAD

Gastón A. Rodriguez-Granillo, MD; Raquel del Valle, MD; Jurgen Ligthart, BSc; Patrick W. Serruys*, MD, PhD

Thin-cap fibro atheroma (TCFA) lesions, the most prevalent precursor of plaque rupture, are composed of a lipid-rich necrotic core, a thin-fibrous cap with macrophage and lymphocyte infiltration, decreased smooth muscle cell content and expansive remodeling. Virtual Histology™ uses spectral analysis of intravascular ultrasound (IVUS) radiofrequency data to construct tissue maps that classify plaque into four major components; calcified, fibrous, fibrolipidic and necrotic core regions that are labeled white, green, greenish-yellow and red respectively. Palpography™ evaluates in vivo the mechanical properties of plaque tissue. The local strain is calculated from the radiofrequency traces using cross-correlation analysis and displayed, colour coded, from blue (for 0% strain) through yellow (for 2% strain) via red (Figure 1).

At a defined pressure, soft tissue (lipid-rich) components will deform more than hard (fibrous-calcified) components. Both techniques have been previously validated1,2.

Figure 1a shows an angiographically non-diseased proximal left anterior descending (LAD) artery. IVUS longitudinal reconstruction (Figure 1b) shows diffuse LAD disease. An eccentric mixed plaque that did not compromise the lumen was detected in the proximal LAD (Figure 1c). This segment was further analyzed with Palpography (20 MHz Eagle Eye, Volcano Therapeutics) and Virtual Histology™ (30 MHz Ultracross, Boston Scientific Corp) (Figures 1d and 1e). Despite its innocuous appearance on gray-scale IVUS, highly deformable shoulders with an underlying necrotic core-rich substrate were detected with the aid of strain and compositional imaging.

Although compatible with the presence of a vulnerable plaque, the prognostic value of these findings is currently unknown and needs to be established in large prospective randomized trials. Thus, the patient was discharged on intensive systemic therapy including lipid-lowering agents.

Figure 1. LAD= left anterior descending coronary artery. LCx= Left circumflex coronary artery. LMCA= Left main coronary artery. * Pericardium.

Volume 1 Number 3
Nov 20, 2005
Volume 1 Number 3
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-E-25-00029 Aug 4, 2025
Coronary sinus Reducer for the treatment of refractory angina: how much more evidence do we need?
Al-Lamee R and Foley M
free

Expert Review

10.4244/EIJ-D-24-00812 Aug 4, 2025
Management of device embolisation during left atrial appendage closure
Kefer J et al
free

Research Correspondence

10.4244/EIJ-D-24-01123 Aug 4, 2025
Coronary sinus narrowing for the treatment of refractory angina: one-year results of the REDUCER-I study
Verheye S et al

Editorial

10.4244/EIJ-E-25-00030 Aug 4, 2025
Expanding the boundaries of M-TEER: is it time to treat moderate secondary mitral regurgitation?
Adamo M and Riccardi M
free

Editorial

10.4244/EIJ-E-25-00035 Aug 4, 2025
The promise and pitfalls of registries for transcatheter tricuspid valve intervention
Hahn R
free

Original Research

10.4244/EIJ-D-24-01174 Aug 4, 2025
Transcatheter valve repair of tricuspid regurgitation: 1-year outcomes from the TriCLASP study
Baldus S et al
Trending articles
172.65

Focus article

10.4244/EIJY19M08_01 Jan 17, 2020
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Glikson M et al
free
95.95

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
63

Image – Interventional flashlight

10.4244/EIJ-D-22-00074 Jun 3, 2022
Transcatheter aortic valve repair for aortic regurgitation with the Cusper device
Feld Y et al
free
58.55

Clinical research

10.4244/EIJ-D-23-00344 Sep 18, 2023
Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
Sanchez-Luna JP et al
free
49.1

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
49.1

Original Research

10.4244/EIJ-D-25-00331 Jul 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
31.35

Expert Review

10.4244/EIJ-D-24-00535 May 5, 2025
Catheter-based techniques for pulmonary embolism treatment
Costa F et al
30.4

Clinical Research

10.4244/EIJ-D-21-00363 Jan 28, 2022
Membranous septum morphology and risk of conduction abnormalities after transcatheter aortic valve implantation
Jørgensen T et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved